<VariationArchive VariationID="1452278" VariationName="NM_000487.6(ARSA):c.1136del (p.Pro379fs)" VariationType="Deletion" Accession="VCV001452278" Version="6" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-03-05" DateCreated="2022-03-28" MostRecentSubmission="2024-02-28">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="1363999" VariationID="1452278">
      <GeneList>
        <Gene Symbol="ARSA" FullName="arylsulfatase A" GeneID="410" HGNC_ID="HGNC:713" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>22q13.33</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="50622754" stop="50628152" display_start="50622754" display_stop="50628152" Strand="-" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="51061181" stop="51066600" display_start="51061181" display_stop="51066600" Strand="-" />
          </Location>
          <OMIM>607574</OMIM>
        </Gene>
      </GeneList>
      <Name>NM_000487.6(ARSA):c.1136del (p.Pro379fs)</Name>
      <CanonicalSPDI>NC_000022.11:50625652:GGG:GG</CanonicalSPDI>
      <VariantType>Deletion</VariantType>
      <Location>
        <CytogeneticLocation>22q13.33</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="22" Accession="NC_000022.11" start="50625653" stop="50625653" display_start="50625653" display_stop="50625653" variantLength="1" positionVCF="50625652" referenceAlleleVCF="CG" alternateAlleleVCF="C" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="22" Accession="NC_000022.10" start="51064081" stop="51064081" display_start="51064081" display_stop="51064081" variantLength="1" positionVCF="51064080" referenceAlleleVCF="CG" alternateAlleleVCF="C" />
      </Location>
      <ProteinChange>P293fs</ProteinChange>
      <ProteinChange>P379fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001362782.2" sequenceAccession="NM_001362782" sequenceVersion="2" change="c.878del">
            <Expression>NM_001362782.2:c.878del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001349711.1" sequenceAccession="NP_001349711" sequenceVersion="1" change="p.Pro293fs">
            <Expression>NP_001349711.1:p.Pro293fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.10" sequenceAccession="NC_000022" sequenceVersion="10" change="g.51064083del" Assembly="GRCh37">
            <Expression>NC_000022.10:g.51064083del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000022.11" sequenceAccession="NC_000022" sequenceVersion="11" change="g.50625655del" Assembly="GRCh38">
            <Expression>NC_000022.11:g.50625655del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_009260.2" sequenceAccession="NG_009260" sequenceVersion="2" change="g.7527del">
            <Expression>NG_009260.2:g.7527del</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000487.6" sequenceAccession="NM_000487" sequenceVersion="6" change="c.1136del" MANESelect="true">
            <Expression>NM_000487.6:c.1136del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000478.3" sequenceAccession="NP_000478" sequenceVersion="3" change="p.Pro379fs">
            <Expression>NP_000478.3:p.Pro379fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001085425.3" sequenceAccession="NM_001085425" sequenceVersion="3" change="c.1136del">
            <Expression>NM_001085425.3:c.1136del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001078894.2" sequenceAccession="NP_001078894" sequenceVersion="2" change="p.Pro379fs">
            <Expression>NP_001078894.2:p.Pro379fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001085426.3" sequenceAccession="NM_001085426" sequenceVersion="3" change="c.1136del">
            <Expression>NM_001085426.3:c.1136del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001078895.2" sequenceAccession="NP_001078895" sequenceVersion="2" change="p.Pro379fs">
            <Expression>NP_001078895.2:p.Pro379fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001085427.3" sequenceAccession="NM_001085427" sequenceVersion="3" change="c.1136del">
            <Expression>NM_001085427.3:c.1136del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001078896.2" sequenceAccession="NP_001078896" sequenceVersion="2" change="p.Pro379fs">
            <Expression>NP_001078896.2:p.Pro379fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_001085428.3" sequenceAccession="NM_001085428" sequenceVersion="3" change="c.878del">
            <Expression>NM_001085428.3:c.878del</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_001078897.1" sequenceAccession="NP_001078897" sequenceVersion="1" change="p.Pro293fs">
            <Expression>NP_001078897.1:p.Pro293fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="rs" ID="2146717905" DB="dbSNP" />
      </XRefList>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000487.6(ARSA):c.1136del (p.Pro379fs) AND Metachromatic leukodystrophy" Accession="RCV001994511" Version="5">
        <ClassifiedConditionList TraitSetID="787">
          <ClassifiedCondition DB="MedGen" ID="C0023522">Metachromatic leukodystrophy</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>criteria provided, single submitter</ReviewStatus>
            <Description DateLastEvaluated="2021-03-25" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="2021-03-25" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2022-03-28" MostRecentSubmission="2024-02-28">
        <ReviewStatus>criteria provided, single submitter</ReviewStatus>
        <Description>Pathogenic</Description>
        <ConditionList>
          <TraitSet ID="787" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5508" Type="Disease">
              <Name>
                <ElementValue Type="Preferred">Metachromatic leukodystrophy</ElementValue>
                <XRef ID="Metachromatic+leukodystrophy/4691" DB="Genetic Alliance" />
                <XRef ID="MONDO:0018868" DB="MONDO" />
                <XRef ID="396338004" DB="SNOMED CT" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">Metachromatic leukoencephalopathy</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Sulfatide lipidosis</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebral sclerosis diffuse metachromatic form</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Cerebroside sulfatase deficiency</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Arylsulfatase A Deficiency</ElementValue>
                <XRef ID="NBK1130" DB="GeneReviews" />
              </Name>
              <Symbol>
                <ElementValue Type="Preferred">MLD</ElementValue>
                <XRef Type="MIM" ID="250100" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="public definition">Arylsulfatase A deficiency (also known as metachromatic leukodystrophy or MLD) is characterized by three clinical subtypes: late-infantile MLD, juvenile MLD, and adult MLD. Age of onset within a family is usually similar. The disease course may be from several years in the late-infantile-onset form to decades in the juvenile- and adult-onset forms. Late-infantile MLD. Onset is before age 30 months. Typical presenting findings include weakness, hypotonia, clumsiness, frequent falls, toe walking, and dysarthria. As the disease progresses, language, cognitive, and gross and fine motor skills regress. Later signs include spasticity, pain, seizures, and compromised vision and hearing. In the final stages, children have tonic spasms, decerebrate posturing, and general unawareness of their surroundings. Juvenile MLD. Onset is between age 30 months and 16 years. Initial manifestations include decline in school performance and emergence of behavioral problems, followed by gait disturbances. Progression is similar to but slower than in the late-infantile form. Adult MLD. Onset occurs after age 16 years, sometimes not until the fourth or fifth decade. Initial signs can include problems in school or job performance, personality changes, emotional lability, or psychosis; in others, neurologic symptoms (weakness and loss of coordination progressing to spasticity and incontinence) or seizures initially predominate. Peripheral neuropathy is common. Disease course is variable – with periods of stability interspersed with periods of decline – and may extend over two to three decades. The final stage is similar to earlier-onset forms.</Attribute>
                <XRef ID="NBK1130" DB="GeneReviews" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="3230" />
                <XRef ID="3230" DB="Office of Rare Diseases" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301309</ID>
                <ID Source="BookShelf">NBK1130</ID>
              </Citation>
              <Citation Type="practice guideline" Abbrev="AAP, 2021">
                <URL>https://publications.aap.org/pediatrics/article/148/3/e2021053126/181065/Leukodystrophies-in-Children-Diagnosis-Care-and</URL>
                <CitationText>Leukodystrophies in Children: Diagnosis, Care, and Treatment, Pediatrics (2021) 148 (3): e2021053126.</CitationText>
              </Citation>
              <XRef ID="512" DB="Orphanet" />
              <XRef ID="C0023522" DB="MedGen" />
              <XRef ID="MONDO:0018868" DB="MONDO" />
              <XRef Type="MIM" ID="250100" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="4253612" SubmissionDate="2024-02-07" DateLastUpdated="2024-02-28" DateCreated="2022-03-28">
        <ClinVarSubmissionID localKey="13411881|MedGen:C0023522" submittedAssembly="GRCh37" />
        <ClinVarAccession Accession="SCV002229807" DateUpdated="2024-02-28" DateCreated="2022-03-28" Type="SCV" Version="3" SubmitterName="Invitae" OrgID="500031" OrganizationCategory="laboratory" OrgAbbreviation="Invitae" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="2021-03-25">
          <ReviewStatus>criteria provided, single submitter</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
          <Comment>This sequence change creates a premature translational stop signal (p.Pro379Argfs*44) in the ARSA gene. While this is not anticipated to result in nonsense mediated decay, it is expected to disrupt the last 131 amino acid(s) of the ARSA protein. For these reasons, this variant has been classified as Pathogenic. This variant disrupts the C-terminus of the ARSA protein. Other variant(s) that disrupt this region (p.Glu483*) have been determined to be pathogenic (Invitae). This suggests that variants that disrupt this region of the protein are likely to be causative of disease. This variant has not been reported in the literature in individuals with ARSA-related conditions. This variant is not present in population databases (ExAC no frequency).</Comment>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <AttributeSet>
          <Attribute Type="AssertionMethod">Invitae Variant Classification Sherloc (09022015)</Attribute>
          <Citation>
            <ID Source="PubMed">28492532</ID>
          </Citation>
        </AttributeSet>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species TaxonomyId="9606">human</Species>
              <AffectedStatus>unknown</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>clinical testing</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">not provided</Attribute>
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="ARSA" />
          </GeneList>
          <VariantType>Variation</VariantType>
          <AttributeSet>
            <Attribute Type="HGVS">NC_000022.10:g.51064081del</Attribute>
          </AttributeSet>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <XRef DB="MedGen" ID="C0023522" Type="CUI" />
          </Trait>
        </TraitSet>
        <SubmissionNameList>
          <SubmissionName>SUB11173117</SubmissionName>
          <SubmissionName>SUB12506961</SubmissionName>
          <SubmissionName>SUB14200269</SubmissionName>
        </SubmissionNameList>
      </ClinicalAssertion>
    </ClinicalAssertionList>
    <TraitMappingList>
      <TraitMapping ClinicalAssertionID="4253612" TraitType="Disease" MappingType="XRef" MappingValue="C0023522" MappingRef="MedGen">
        <MedGen CUI="C0023522" Name="Metachromatic leukodystrophy" />
      </TraitMapping>
    </TraitMappingList>
  </ClassifiedRecord>
</VariationArchive>

